09688 ZAI LABWatchlist
About ZAI LAB Company
Zaiding Pharmaceutical is an innovative biopharmaceutical company based in China and operating globally. It is committed to providing innovative drugs in the fields of cancer, autoimmune and infectious diseases to patients in China and around the world. Zaiding Pharmaceutical is headquartered in Shanghai. Since its establishment in 2014, it has established partnerships with many of the world's leading biopharmaceutical companies to create a broad line of late-stage innovative drug candidates. For global biopharmaceutical companies seeking to enter the Chinese market and find long-term strategic partners for international clinical development, Zaiding Pharmaceutical has become one of the most trustworthy partner candidates in the industry through a series of successful cooperation cases. Through these successful collaborations, Zaiding Pharmaceutical has built the most powerful advanced oncology product pipeline among innovative Chinese biotechnology companies, with many of the world's first of its kind and/or best-in-class drugs. At the same time, we are continuously improving our in-house R&D capabilities to further supplement our product line, with the goal of having 1-2 global new drug clinical trial applications (IND) each year in the future. Zaiding Pharmaceutical is rapidly developing into a fully integrated biopharmaceutical company that discovers, develops, produces and commercializes innovative medicines in China and around the world. To this end, we have set up an internal R&D center in China to promote drug research and development, built a strong clinical development and operation team, and established our own production base. Additionally, we have set up a specialized commercial team to support the promotion of innovative products in China. We believe that this integration strategy will provide Zaiding Pharmaceutical with a sustainable competitive advantage. Zaiding Pharmaceutical was successfully listed on the US NASDAQ in September 2017. Since then, the company has developed rapidly, set up branches or offices in many parts of China, and established an American headquarters in San Francisco in December 2018. As of December 2019, the company had around 700 employees worldwide.
JP Morgan Maintains Overweight on Zai Lab, Raises Price Target to $66
JP Morgan analyst Anupam Rama maintains Zai Lab with a Overweight and raises the price target from $64 to $66.
Zai Lab Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/30/2023 136.86% JP Morgan $64 → $66 Maintains Overweight 10/26/2023 359.36% Citigroup $130 → $128 Maint
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
Asian equities traded in the US as American depositary receipts edged higher Wednesday morning, with the S&P Asia 50 ADR Index advancing 0.08% to 1,670.22. From North Asia, the gainers were led by sol